What were Eli Lilly's Q1 2026 revenues?

Mounjaro and Zepbound alone generated $12.8 billion, with total revenue growing 55.5%.

Why hasn't Eli Lilly's stock risen significantly despite strong results?

The market may have already priced in positive expectations, limiting gains. The relatively weak performance could also reflect valuation concerns.

Can Eli Lilly stock reach $1,500 by 2028?

Some analysts believe the stock could reach $1,500 if sales continue to grow strongly, but it depends on factors like competition and market expansion.

Eli Lilly Q1 Revenue Surges 55.5%, Guidance Raised; Can LLY Hit $1,500 by 2028?

Q: What is Eli Lilly's guidance for 2026?

The company raised its full-year guidance to $82-85 billion.

Eli Lilly (NYSE:LLY) posted a 55.5% revenue surge in Q1 2026, fueled by Mounjaro and Zepbound sales of $12.8 billion. The company raised its full-year guidance to $82-85 billion, yet shares are up just 1.11% year-to-date at $1,082.92. The big question: Can LLY reach $1,500 per share by 2028?

Eli Lilly (NYSE:LLY) delivered exceptional Q1 2026 results, with revenue growing 55.5% year-over-year, driven by blockbuster diabetes and obesity drugs Mounjaro and Zepbound. The two drugs alone generated $12.8 billion in the quarter. Despite this explosive growth, the stock has risen only 1.11% year-to-date to $1,082.92.

Key Financial Results

Metric	Q1 2026	YoY Change
Revenue (Mounjaro & Zepbound)	$12.8B	+55.5%
Full-Year Guidance	$82-85B	Raised
Stock Price	$1,082.92	+1.11% YTD

Highlights from the Report

The company attributed the strong performance to surging demand for its diabetes and obesity treatments, particularly Mounjaro (for diabetes) and Zepbound (for obesity). Lilly also highlighted expansion of its pipeline and manufacturing capacity to meet growing demand.

Future Guidance

Eli Lilly raised its full-year revenue guidance to a range of $82-85 billion, reflecting confidence in continued strong momentum for Mounjaro and Zepbound.

Impact on the Stock

Despite the stellar results, the stock has underperformed year-to-date, possibly indicating that positive expectations were already priced in. However, some analysts believe the stock has room to run if sales continue to beat estimates.

What This Means for Investors

Lilly's strong results present an opportunity for investors seeking exposure to the growing healthcare sector, especially diabetes and obesity treatments. However, the stock may already be fairly valued, and any slowdown in growth could weigh on the price. Investors should closely monitor future guidance and key product sales.